Apellis Pharmaceuticals Investor Presentation — December 2021

Document content

#2194Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and

Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter

1Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany; 2Centre Hospitalier Annecy Genevois , Épagny -Metz -Tessy , France; 3Hematology/Oncology Division, Denver Health and Hospital Authority, Denver, CO, United States; 4French Reference Center for Aplastic Anemia and Paroxysmal Noctural Hemoglobinuria, Assistance Publique -Hôpitaux de Paris; Université de Paris, Paris, France;

5Medical Clinic and Polyclinic II -Hematology, Oncology, University Medical Center Hamburg -Eppendorf, Hamburg, Germany; 6Department of Hematology, Cliniques Universitaires Saint -Luc, Woluwe -Saint -Lambert, Belgium; 7Apellis Pharmaceuticals, Waltham, MA, United States; 8Sir Y .K. Pao Centre for Cancer & Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong

American Society for Hematology |

December 11 -14, 2021 | Atlanta, GA / VirtualREFERENCES: 1. Parker C, et al. Blood . 2005;106(12):3699 -3709. 2. Hillmen P, et al. N Engl J Med. 2021;384(11):1028 -1037. 3. Wong RS, et al., Blood. 2020 136 [Supplement 1]. 4. Wong RS, et al., Blood . 2021 138 [November Supplement]. 5. Cella D, et al. J Pain Symptom Manage. 2002;24(6):547 -561. 6. Montan I, et al. Value Health. 2018 Nov;21(11):1313 -1321.

ACKNOWLEDGEMENTS: The patients who participated in the PADDOCK, PEGASUS and PRINCE studies, as well as their caregivers; Institution staff and investigators who participated in this study and for their valuable contributions; Writing and editorial support were provided b y Boston Strategic Partners Inc. (supported by Apellis Pharmaceuticals, Inc.); Apellis Pharmaceuticals and Swedish Orphan Biovitrum AB reviewed the presentation; This study was supported by Apellis Pharmaceuticals, Inc.

DISCLOSURES: Panse , J:Reports consultancy, honoraria, and membership on an entity's Board of Directors or advisory committees with Blueprint Medici nes, Amgen, F. Hoffmann -La Roche Ltd, MSD, Grünenthal , Bristol Myers Squibb, and Apellis Pharmaceuticals, Inc. Reports speakers bureau with Chugai Pharmaceutical Co., Pfizer, Nov artis, Boehringer Ingelheim, and Alexion Pharmaceuticals, Inc. Reports membership on an entity's Board of Directors or advisory committees with Novartis, Boehringer Ingelheim, and Alexion Pharmaceuticals, Inc.; Daguindau , N & Okuyama , S:

Preview truncated — download the full document for the complete content.